200 related articles for article (PubMed ID: 19779332)
1. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy.
Sauer AV; Aiuti A
Curr Opin Allergy Clin Immunol; 2009 Dec; 9(6):496-502. PubMed ID: 19779332
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
3. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
4. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.
Ferrua F; Brigida I; Aiuti A
Curr Opin Allergy Clin Immunol; 2010 Dec; 10(6):551-6. PubMed ID: 20966749
[TBL] [Abstract][Full Text] [Related]
5. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
6. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
[TBL] [Abstract][Full Text] [Related]
7. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
[TBL] [Abstract][Full Text] [Related]
8. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy.
Sauer AV; Morbach H; Brigida I; Ng YS; Aiuti A; Meffre E
J Clin Invest; 2012 Jun; 122(6):2141-52. PubMed ID: 22622038
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Montiel-Equihua CA; Thrasher AJ; Gaspar HB
Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
[TBL] [Abstract][Full Text] [Related]
11. Advances in gene therapy for ADA-deficient SCID.
Aiuti A
Curr Opin Mol Ther; 2002 Oct; 4(5):515-22. PubMed ID: 12435054
[TBL] [Abstract][Full Text] [Related]
12. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
Smogorzewska EM; Weinberg KI; Kohn DB
Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
14. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
Gaspar HB
Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.
Sauer AV; Brigida I; Carriglio N; Hernandez RJ; Scaramuzza S; Clavenna D; Sanvito F; Poliani PL; Gagliani N; Carlucci F; Tabucchi A; Roncarolo MG; Traggiai E; Villa A; Aiuti A
Blood; 2012 Feb; 119(6):1428-39. PubMed ID: 22184407
[TBL] [Abstract][Full Text] [Related]
18. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
20. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
